Skip to main content
Top
Published in: BMC Infectious Diseases 1/2016

Open Access 01-12-2016 | Research article

Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin

Authors: Marco Gelpi, Hans J. Hartling, Kristina Thorsteinsson, Jan Gerstoft, Henrik Ullum, Susanne D. Nielsen

Published in: BMC Infectious Diseases | Issue 1/2016

Login to get access

Abstract

Background

Symptomatic primary HIV infection is associated with an adverse prognosis, and immediate initiation of combination antiretroviral therapy (cART) is recommended. However, little is known about immunological predictors of immune recovery. Thymic Stromal Lymphopoietin (TSLP) is a cytokine that promotes CD4+ T cells homeostatic polyclonal proliferation and regulates Th17/regulatory T-cell balance, immunological functions known to be affected during primary HIV infection. The aim of this study was to describe immune recovery in primary and chronic HIV infection and possible impact of TSLP.

Methods

Prospective study including 100 HIV-infected individuals (primary HIV infection (N = 14), early presenters (>350 CD4+ T cells/μL, N = 42), late presenters without advanced disease (200–350 CD4+ T cells/μL, N = 24) and with advanced disease (<200 CD4+ T cells/μL, N = 20) and). Immune recovery was defined as increase in CD4+ T cells count from baseline to a given time of follow-up. Plasma TSLP was determined using ELISA and CD4+ T cell subpopulations (recent thymic emigrants, naïve and memory cells) were measured using flow cytometry at baseline and after 6, 12 and 24 months of cART.

Results

Immune recovery was comparable in all groups, and no differences in immune homeostasis were found between primary HIV infection and early presenters, whereas differences in absolute counts and proportions of CD4+ T cell subpopulations were found between primary HIV infection and late presenters. TSLP was elevated in primary HIV infection at baseline and after 24 months of cART. Interestingly, TSLP was negatively associated with proportion of recent thymic emigrants (correlation coefficient −0.60, p = 0.030). TSLP was not associated with immune recovery in primary HIV infection.

Conclusions

Immune recovery was comparable in primary and chronic HIV infection whereas differences in absolute counts and proportions of CD4+ T cell subpopulations were found between primary HIV infection and late presenters supporting early initiation of cART. Higher plasma TSLP was found in primary HIV infection, and TSLP was associated with lower thymic output, but not with immune recovery. These findings indicate a possible role of TSLP in immune homeostasis in HIV infection but do not support TSLP to affect immune recovery in primary HIV infection.
Literature
4.
go back to reference Lindback S, Brostrom C, Karlsson A, Gaines H, Brostrm C. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 x 10(6)/l, AIDS, and death from AIDS? BMJ. 1994;1984:4–6. Lindback S, Brostrom C, Karlsson A, Gaines H, Brostrm C. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 x 10(6)/l, AIDS, and death from AIDS? BMJ. 1994;1984:4–6.
6.
go back to reference Vanhems P, Beaulieu R. HIV medicine Primary infection by type 1 human immunodeficiency virus : diagnosis and prognosis. Postgr Med J. 1997;73:403–8.CrossRef Vanhems P, Beaulieu R. HIV medicine Primary infection by type 1 human immunodeficiency virus : diagnosis and prognosis. Postgr Med J. 1997;73:403–8.CrossRef
7.
go back to reference Pantazis N, Touloumi G, Meyer L, Olson A, Costagliola D, Kelleher AD, et al. The impact of transient cART in early HIV infection on viral suppression and immunologic response in later treatment. AIDS. 2015;30(6):879–88.CrossRef Pantazis N, Touloumi G, Meyer L, Olson A, Costagliola D, Kelleher AD, et al. The impact of transient cART in early HIV infection on viral suppression and immunologic response in later treatment. AIDS. 2015;30(6):879–88.CrossRef
12.
go back to reference Schuetz A, Deleage C, Sereti I, Rerknimitr R, Phanuphak N, Phuang-ngern Y, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. 2014;10(12):e1004543.CrossRefPubMedPubMedCentral Schuetz A, Deleage C, Sereti I, Rerknimitr R, Phanuphak N, Phuang-ngern Y, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. 2014;10(12):e1004543.CrossRefPubMedPubMedCentral
15.
go back to reference Benito JM, López M, Lozano S, González-Lahoz J, Soriano V. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy. J Infect Dis. 2008;198:1466–73.CrossRefPubMed Benito JM, López M, Lozano S, González-Lahoz J, Soriano V. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy. J Infect Dis. 2008;198:1466–73.CrossRefPubMed
16.
go back to reference Rethi B, Fluur C, Atlas A, Krzyzowska M, Mowafi F, Grützmeier S, et al. Loss of IL-7Ralpha is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients. AIDS. 2005;19:2077–86.CrossRefPubMed Rethi B, Fluur C, Atlas A, Krzyzowska M, Mowafi F, Grützmeier S, et al. Loss of IL-7Ralpha is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients. AIDS. 2005;19:2077–86.CrossRefPubMed
17.
go back to reference Fluur C, Rethi B, Thang PH, Vivar N, Mowafi F, Lopalco L, et al. Relationship between serum IL-7 concentrations and lymphopenia upon different levels of HIV immune control. AIDS. 2007;21:1048–50.CrossRefPubMed Fluur C, Rethi B, Thang PH, Vivar N, Mowafi F, Lopalco L, et al. Relationship between serum IL-7 concentrations and lymphopenia upon different levels of HIV immune control. AIDS. 2007;21:1048–50.CrossRefPubMed
18.
go back to reference Rajasuriar R, Booth D, Solomon A, Chua K, Spelman T, Gouillou M, et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. J Infect Dis. 2010;202:1254–64.CrossRefPubMed Rajasuriar R, Booth D, Solomon A, Chua K, Spelman T, Gouillou M, et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. J Infect Dis. 2010;202:1254–64.CrossRefPubMed
20.
go back to reference Camargo JF, Kulkarni H, Agan BK, Gaitan AA, Beachy LA, Srinivas S, et al. Responsiveness of T cells to interleukin-7 is associated with higher CD4+ T cell counts in HIV-1-positive individuals with highly active antiretroviral therapy-induced viral load suppression. J Infect Dis. 2009;199:1872–82.CrossRefPubMedPubMedCentral Camargo JF, Kulkarni H, Agan BK, Gaitan AA, Beachy LA, Srinivas S, et al. Responsiveness of T cells to interleukin-7 is associated with higher CD4+ T cell counts in HIV-1-positive individuals with highly active antiretroviral therapy-induced viral load suppression. J Infect Dis. 2009;199:1872–82.CrossRefPubMedPubMedCentral
25.
go back to reference Watanabe N, Wang Y-H, Lee HK, Ito T, Wang Y-H, Cao W, et al. Hassall’s corpuscles instruct dendritic cells to induce CD4 + CD25+ regulatory T cells in human thymus. Nature. 2005;436:1181–5.CrossRefPubMed Watanabe N, Wang Y-H, Lee HK, Ito T, Wang Y-H, Cao W, et al. Hassall’s corpuscles instruct dendritic cells to induce CD4 + CD25+ regulatory T cells in human thymus. Nature. 2005;436:1181–5.CrossRefPubMed
30.
go back to reference Palmer BE, Blyveis N, Fontenot AP, Wilson CC. Functional and phenotypic characterization of CD57 + CD4+ T cells and their association with HIV-1-induced T cell dysfunction. J Immunol. 2005;175:8415–23.CrossRefPubMed Palmer BE, Blyveis N, Fontenot AP, Wilson CC. Functional and phenotypic characterization of CD57 + CD4+ T cells and their association with HIV-1-induced T cell dysfunction. J Immunol. 2005;175:8415–23.CrossRefPubMed
33.
go back to reference Watanabe N, Hanabuchi S, Marloie-Provost MA, Antonenko S, Liu YJ, Soumelis V. Human TSLP promotes CD40 ligand-induced IL-12 production by myeloid dendritic cells but maintains their Th2 priming potential. Blood. 2005;105:4749–51.CrossRefPubMed Watanabe N, Hanabuchi S, Marloie-Provost MA, Antonenko S, Liu YJ, Soumelis V. Human TSLP promotes CD40 ligand-induced IL-12 production by myeloid dendritic cells but maintains their Th2 priming potential. Blood. 2005;105:4749–51.CrossRefPubMed
35.
go back to reference Spadoni I, Iliev ID, Rossi G, Rescigno M. Dendritic cells produce TSLP that limits the differentiation of Th17 cells, fosters Treg development, and protects against colitis. Mucosal Immunol. [Internet]. Nat Publ Group. 2012;5:184–93. Available from: http://dx.doi.org/10.1038/mi.2011.64. Spadoni I, Iliev ID, Rossi G, Rescigno M. Dendritic cells produce TSLP that limits the differentiation of Th17 cells, fosters Treg development, and protects against colitis. Mucosal Immunol. [Internet]. Nat Publ Group. 2012;5:184–93. Available from: http://​dx.​doi.​org/​10.​1038/​mi.​2011.​64.
Metadata
Title
Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin
Authors
Marco Gelpi
Hans J. Hartling
Kristina Thorsteinsson
Jan Gerstoft
Henrik Ullum
Susanne D. Nielsen
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-1930-3

Other articles of this Issue 1/2016

BMC Infectious Diseases 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.